• General anesthesia:
    • 0-1 month neonate:
      • 3.3% in oxygen
    • 1-6 months:
      • 3% oxygen
    • 6 months – < 3 years:
      • 8% in oxygen or 2 % with 65% N2O/35% oxygen
    • 3-12 years:
      • 5% in oxygen or 2.5 % with 65% N2O/35% oxygen
    • 12-25 years:
      • 6% in oxygen or 1.4% with 65% N2O/35% oxygen
    • 25-40 years:
      • 1% in oxygen or 1.1% with 65% N2O/35% oxygen
    • 40-60 years:
      • 7% in oxygen or 0.9% with 65% N2O/35% oxygen
    • 60-80 years:
      • 4% in oxygen or 0.7% with 65% N2O/35% oxygen

Solution: 100%

Individualize dose

General anesthetic

It is thought to alter the neuronal ion channels such as GABA, glutamate and glycine receptors resulting in decreased tissue excitability.

  • Nausea
  • Vomiting
  • Agitation
  • Cough
  • Hypotension
  • Laryngospasm
  • Breath holding
  • Bradycardia
  • Tachycardia
  • Airway obstruction
  • Somnolence
  • Shivering
  • Sialorrhea
  • Dizziness
  • Hypertension
  • Apnea
  • Known or suspected malignant hyperthermia risk
  • Infantile-onset pompe disease
  • Lack of ventilatory support
  • Cisapride
  • Dronedarone
  • Levoketoconazole
  • Pimozide
  • Thioridazine

                          Drug Status

Availability Prescription only
Pregnancy Weigh risk vs benefit
Breastfeeding Weigh risk vs benefit
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Sevoflurane 250mL Inhalation solution 1’s Piramal Enterprises Galaxy Pharma
Sevotroy 250mL Inhalation solution 1’s Troikaa Harley’s Ltd
Ultane 250mL Inhalation solution 1’s Abbvie Phillips Therapeutics